<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01635231</url>
  </required_header>
  <id_info>
    <org_study_id>EBP-JMJ-2012-1</org_study_id>
    <nct_id>NCT01635231</nct_id>
  </id_info>
  <brief_title>The Effect of Thiazide, Amiloride and Hypertonic Saline on Urinary Biomarkers in Healthy Subjects</brief_title>
  <acronym>THAM</acronym>
  <official_title>Effect of Thiazide, Amiloride and Hypertonic Saline on Sodium- and Water Channel Activity in the Nephron in Healthy Subjects Estimated by Urinary Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regional Hospital Holstebro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regional Hospital Holstebro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Urinary biomarkers (u-NKCC2, u-ENaC-gamma and u-AQP2) reflects the activity of the sodium-&#xD;
      and water channels in the human kidney.&#xD;
&#xD;
      Changes in the sodium-and water channel activity can be induced by blocking the sodium&#xD;
      channels with diuretics in healthy subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Urinary biomarkers (u-NKCC2, u-ENaC-gamma and u-AQP2) reflects the kidneys transport of&#xD;
           sodium and water in the nephron.&#xD;
&#xD;
        2. Changes in the sodium-and water channel activity is induced by blocking the NCC channels&#xD;
           with thiazide and ENaC channels with amiloride and by intervention with hypertonic NaCl&#xD;
           The changes in sodium-and water channels are followed by changes in extracellular and&#xD;
           intracellular fluids, central bloodpressure and the plasma concentration of vasoactive&#xD;
           hormones.&#xD;
&#xD;
      The purpose of this study is to investigate the changes in urinary biomarkers (u-NKCC2,&#xD;
      u-ENaC-gamma and u-AQP2), extra- and intracellular fluid compartments, central bloodpressure&#xD;
      and the plasma concentration of Vasoactive hormones in healthy subjects under a) treatment&#xD;
      with Amiloride and Thiazide at baseline and b) after and acute infusion with hypertonic&#xD;
      saline.&#xD;
&#xD;
      Subjects will be examined on three examination days. Four days prior to the examination days&#xD;
      the subjects will consume a standard diet based on amount of sodium and calories and&#xD;
      randomized to treatment with either thiazide, amiloride or placebo twice daily for 5 days. On&#xD;
      the examination days the subjects receive an infusion with hypertonic saline.&#xD;
&#xD;
      Renal function is measured by renal clearance of 51Cr-EDTA. Urinary biomarkers (u-NKCC2,&#xD;
      u-ENaC-gamma and u-AQP2) will be measured to evaluate the activity of water- and sodium&#xD;
      channels in the nephron, changes in fluid compartments are measured by body composition&#xD;
      monitor. Central blood pressure is measured by sphygmocor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>urinary biomarkers</measure>
    <time_frame>baseline, 0 hours and 1.5 hours after intervention</time_frame>
    <description>Urinary excretion of epithelial sodium channels (ENaC), Sodium-potassium-2chloride transporters (NKCC2) and aquaporin2 channels (AQP2) before, during and after fluid infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>vaso active hormones</measure>
    <time_frame>baseline, 0 hours and 1.5 hours after intervention</time_frame>
    <description>plasma concentrations of: renin, Angiotensin II, aldosterone, Vasopressin, ANP and BNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>central blood pressure</measure>
    <time_frame>baseline, 0 hours and 1.5 hours after intervention</time_frame>
    <description>measured by applanation-tonometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intracellular (ICV)- and extracellular volume (ECV)</measure>
    <time_frame>baseline, 0 hours and 1.5 hours after intervention</time_frame>
    <description>change in ICV and EVC from baseline and after intervention measured in liters by body composition monitor (BCM)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Nephropathy</condition>
  <arm_group>
    <arm_group_label>thiazide, diuretic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.25 mg thiazide twice daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>amiloride, diuretic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mg of amiloride twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>calcium</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo twice daily for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>hypertonic saline</intervention_name>
    <description>hypertonic saline 3.0% 7 ml/kg</description>
    <arm_group_label>amiloride, diuretic</arm_group_label>
    <arm_group_label>calcium</arm_group_label>
    <arm_group_label>thiazide, diuretic</arm_group_label>
    <other_name>NaCl 3.0 %</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy males and females&#xD;
&#xD;
          -  age 18-45&#xD;
&#xD;
          -  BMI range 18,5-30,0 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hypertension (i.e. ambulatory BP &gt; 130 mmHg systolic or/and &gt; 80 mmHg diastolic)&#xD;
&#xD;
          -  history or clinical significant signs of heart, lung, liver, kidney, endocrine, brain&#xD;
             or neoplastic&#xD;
&#xD;
          -  disease.&#xD;
&#xD;
          -  alcohol abuse&#xD;
&#xD;
          -  drug abuse&#xD;
&#xD;
          -  smoking&#xD;
&#xD;
          -  pregnancy or nursing&#xD;
&#xD;
          -  blood donation within a month prior to examination&#xD;
&#xD;
          -  medical treatment apart from oral contraception abnormal blood samples, -ECG and&#xD;
             -urine dipstick, drug abuse, alcohol abuse, pregnancy, medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erling B Pedersen, MD, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Medical Research, Holstebro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Research</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>June 13, 2012</study_first_submitted>
  <study_first_submitted_qc>July 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2012</study_first_posted>
  <last_update_submitted>March 1, 2014</last_update_submitted>
  <last_update_submitted_qc>March 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Regional Hospital Holstebro</investigator_affiliation>
    <investigator_full_name>Erling Bjerregaard Pedersen</investigator_full_name>
    <investigator_title>Ph.d student Janni Majgaard Jensen</investigator_title>
  </responsible_party>
  <keyword>Nephrology</keyword>
  <keyword>sodium-channels</keyword>
  <keyword>water-channels</keyword>
  <keyword>BCM</keyword>
  <keyword>central blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

